CR20230258A - Compuestos y composiciones de moléculas pequeñas - Google Patents

Compuestos y composiciones de moléculas pequeñas

Info

Publication number
CR20230258A
CR20230258A CR20230258A CR20230258A CR20230258A CR 20230258 A CR20230258 A CR 20230258A CR 20230258 A CR20230258 A CR 20230258A CR 20230258 A CR20230258 A CR 20230258A CR 20230258 A CR20230258 A CR 20230258A
Authority
CR
Costa Rica
Prior art keywords
compositions
small molecule
compounds
molecule compounds
methods
Prior art date
Application number
CR20230258A
Other languages
English (en)
Inventor
Katherine Widdowson
Adrian Hall
James William Myatt
Santosh Kulkarni
Mairi Sime
Mark Patrick Healy
David George Hubert Livermore
Robert Joseph Allen Bell
Original Assignee
Telo Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Telo Therapeutics Inc filed Critical Telo Therapeutics Inc
Publication of CR20230258A publication Critical patent/CR20230258A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

En la presente se proporcionan compuestos y composiciones que inhiben la telomerasa y/o el gen de TERT con un promotor mutante. Además, se proporcionan compuestos o composiciones de moléculas pequeñas que tienen efectos beneficiosos<br /> en el tratamiento contra el cáncer. También se proporcionan métodos para elaborar los compuestos y las composiciones y métodos para usar los compuestos y las composiciones, tales como el uso de los compuestos y las composiciones para tratar<br /> el cáncer.
CR20230258A 2020-11-19 2021-11-19 Compuestos y composiciones de moléculas pequeñas CR20230258A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063115650P 2020-11-19 2020-11-19
US202163162049P 2021-03-17 2021-03-17
US202163278041P 2021-11-10 2021-11-10
PCT/US2021/060000 WO2022109209A1 (en) 2020-11-19 2021-11-19 Small molecule compounds and compositions

Publications (1)

Publication Number Publication Date
CR20230258A true CR20230258A (es) 2023-09-12

Family

ID=81709818

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20230258A CR20230258A (es) 2020-11-19 2021-11-19 Compuestos y composiciones de moléculas pequeñas

Country Status (16)

Country Link
US (1) US20230416202A1 (es)
EP (1) EP4247374A4 (es)
JP (1) JP2023550473A (es)
KR (1) KR20230123954A (es)
AU (1) AU2021383768A1 (es)
BR (1) BR112023009665A2 (es)
CA (1) CA3202720A1 (es)
CL (1) CL2023001448A1 (es)
CO (1) CO2023007839A2 (es)
CR (1) CR20230258A (es)
EC (1) ECSP23044970A (es)
IL (1) IL303056A (es)
MX (1) MX2023005943A (es)
PE (1) PE20242103A1 (es)
TW (1) TW202235071A (es)
WO (1) WO2022109209A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202305359D0 (en) * 2023-04-12 2023-05-24 Univ Oxford Innovation Ltd Process
WO2026019666A1 (en) * 2024-07-15 2026-01-22 Telo Therapeutics, Inc. Piperidine compounds

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5741800A (en) * 1993-06-22 1998-04-21 Knoll Aktiengesellachaft Azolyl-cyclic amine derivates with immunomodulatory activity
GB9312806D0 (en) * 1993-06-22 1993-08-04 Boots Co Plc Therapeutic agents
CN1856490A (zh) * 2003-07-28 2006-11-01 詹森药业有限公司 苯并咪唑、苯并噻唑和苯并噁唑衍生物及其作为lta4h调节剂的应用
GB0423356D0 (en) * 2004-10-21 2004-11-24 Merck Sharp & Dohme Therapeutic agents
DE102009022892A1 (de) * 2009-05-27 2010-12-02 Bayer Schering Pharma Aktiengesellschaft Substituierte Piperidine
WO2012162249A1 (en) * 2011-05-20 2012-11-29 Benjamin Wolozin Identification of compounds that disperse tdp-43 inclusions

Also Published As

Publication number Publication date
MX2023005943A (es) 2023-08-11
WO2022109209A1 (en) 2022-05-27
EP4247374A1 (en) 2023-09-27
US20230416202A1 (en) 2023-12-28
KR20230123954A (ko) 2023-08-24
PE20242103A1 (es) 2024-10-28
TW202235071A (zh) 2022-09-16
BR112023009665A2 (pt) 2023-12-12
AU2021383768A1 (en) 2023-06-29
AU2021383768A9 (en) 2024-05-02
ECSP23044970A (es) 2023-08-31
CO2023007839A2 (es) 2023-10-09
CL2023001448A1 (es) 2023-10-30
CA3202720A1 (en) 2022-05-27
IL303056A (en) 2023-07-01
EP4247374A4 (en) 2024-10-09
JP2023550473A (ja) 2023-12-01

Similar Documents

Publication Publication Date Title
MX2024014142A (es) Novedosos inhibidores de molecula peque?a de factores de transcripcion tead
PH12019501116A1 (en) Compounds with anti-tumor activity against cancer cells bearing egfr or her2 exon 20
MX2022001607A (es) Composiciones y metodos para tratar la psoriasis y la dermatitis atopica usando prevotella histicola.
WO2021183318A3 (en) Methods and compositions relating to improved combination therapies
PH12021552395A1 (en) Compounds with anti-tumor activity against cancer cells bearing egfr or her2 exon 20 insertions
MX2023011883A (es) Terapias combinadas con compuestos inhibidores de cbl-b.
MX2010004074A (es) Combinacion 059.
WO2023107574A3 (en) Lipid-based compositions and methods thereof
WO2021207651A3 (en) Chemically modified guide rnas for genome editing with cas12b
PH12022550124A1 (en) Enzyme inhibitors
WO2024006292A3 (en) Methods of treating cancer
BR112022012273A2 (pt) Composto, pirrolo[3,2-c]piridina, pirrolo[3,2-c]piridazina, indol, método para suprimir a expressão de oncogene em uma célula e método para tratar um paciente com leucemia
CR20230258A (es) Compuestos y composiciones de moléculas pequeñas
ZA202304965B (en) Combination therapy for treating cancer
NZ788988A (en) Conjugates and methods for treating liver fibrosis
WO2024163641A3 (en) Formulations for treating cancer
MX2022011646A (es) Celulas t v delta1+ para el tratamiento de neoplasias mieloides.
WO2021081457A3 (en) Methods and agents for enhancing t cell therapies
WO2023097194A3 (en) Bicyclic therapeutic compounds and methods of use in the treatment of cancer
PH12022551081A1 (en) Cancer treatments targeting cancer stem cells
MX2025004473A (es) Novedosos anticuerpos anti-napi2b y conjugados-anticuerpo-droga basados en ellos, metodos terapeuticos y usos de los mismos
MX2022004524A (es) Tratamiento génico para la enfermedad de alzheimer.
MX2023010512A (es) Agentes de union multiespecificos contra cd40 y cd137 en terapia.
WO2020205632A8 (en) Compounds with anti-tumor activity against cancer cells bearing her2 exon 21 insertions
MX2023006087A (es) Formulaciones liofilizadas de tegavivint.